Clinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res)

Journal PubWeight™ 17524.12‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. 2009 24.11
2 Triple-negative breast cancer: clinical features and patterns of recurrence. 2007 16.79
3 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. 2004 16.51
4 Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. 2004 14.53
5 Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. 2008 14.37
6 The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. 2007 11.56
7 In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. 2003 9.92
8 Breast cancer molecular subtypes respond differently to preoperative chemotherapy. 2005 9.70
9 EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. 2008 9.29
10 Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. 2007 9.21
11 Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. 2011 9.03
12 Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. 2007 8.41
13 Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. 2008 8.17
14 Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. 2014 8.11
15 Clinical features of metastatic bone disease and risk of skeletal morbidity. 2006 7.83
16 Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. 2008 7.39
17 Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. 2009 7.35
18 The interleukin-8 pathway in cancer. 2008 7.12
19 A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. 2006 7.09
20 Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. 2006 6.91
21 Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. 2008 6.91
22 The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. 2009 6.83
23 The androgen axis in recurrent prostate cancer. 2004 6.67
24 Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. 2007 6.59
25 Diagnostic markers for early detection of ovarian cancer. 2008 6.47
26 Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. 2012 6.23
27 X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. 2004 6.22
28 Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. 2013 6.10
29 KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. 2009 6.10
30 Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. 2008 6.03
31 A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. 2009 5.99
32 Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. 2008 5.88
33 Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. 2002 5.84
34 ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. 2007 5.75
35 Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. 2005 5.70
36 Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. 2006 5.69
37 Therapeutic nanoparticles for drug delivery in cancer. 2008 5.67
38 Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. 2007 5.59
39 MicroRNA expression profiles in serous ovarian carcinoma. 2008 5.54
40 An in vivo platform for translational drug development in pancreatic cancer. 2006 5.52
41 Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. 2007 5.51
42 Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. 2008 5.50
43 The double-edged sword of autophagy modulation in cancer. 2009 5.46
44 Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. 2008 5.46
45 Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. 2005 5.44
46 CXCL12 (SDF-1)/CXCR4 pathway in cancer. 2010 5.42
47 Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. 2004 5.40
48 Principles and current strategies for targeting autophagy for cancer treatment. 2011 5.40
49 Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. 2007 5.36
50 Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. 2006 5.21
Next 50